Bastian Höchst | Onco- Immunology | Best Researcher Award

Posted on by Neuroscientists

Dr. Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst,  Institute of Molecular Immunology, MRI, TUM, Germany.

Bastian Höchst is a distinguished molecular immunologist whose career spans groundbreaking research, impactful teaching, and valuable contributions to the scientific community. His academic journey began with a focus on biology and culminated in a doctorate on immune regulation in liver tumors. As a Research Group Leader at the Technical University of Munich, he investigates the complex interplay of immune cells and tissues in acute and chronic inflammation. His pioneering discoveries, such as the mechanisms governing myeloid suppressor cells and immune-regulatory metabolite transfer, have advanced understanding in the field.

Profile

Google Scholar

🌱 Early Academic Pursuits

Bastian Höchst began his academic journey with a passion for understanding the intricate mechanisms of biology. From 1999 to 2005, he pursued his studies in Biology at the University of Bonn and Hamburg, laying the foundation for his future endeavors in molecular immunology. His academic curiosity led him to pursue a doctorate at the Medical School Hannover under the guidance of Prof. Dr. Tim F. Greten. His doctoral research focused on identifying and characterizing myeloid-derived suppressor cells in patients with hepatocellular carcinoma, marking the beginning of his impactful contributions to the field of immunology.

🔬 Professional Endeavors

Currently serving as a Research Group Leader at the Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich (TUM), Bastian Höchst has dedicated his career to unraveling the complexities of immune regulation. His journey in academia has been marked by significant roles, including his previous tenure as a Research Group Leader at the Institute for Animal Physiology and Immunology, Wissenschaftszentrum Weihenstephan, TUM. Additionally, his postdoctoral fellowship at the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn further honed his expertise in immune mechanisms.

🧪 Contributions and Research Focus

Bastian Höchst’s research delves into immune regulation within acute and chronic inflammatory processes, with a particular focus on tissue-specific mechanisms. He has made groundbreaking discoveries, including elucidating the pathways that govern the generation of myeloid suppressor cells in liver tumors. Furthermore, his innovative work revealed that the intercellular transfer of immune-regulatory metabolites is critical to T-cell effector functions. His research has significantly advanced the understanding of immune responses in disease contexts, bridging gaps in immunological knowledge.

🎓 Teaching and Mentorship

A dedicated educator, Bastian Höchst has been actively involved in teaching since 2010, inspiring students in life sciences programs at TUM. His lectures on topics such as onco-immunology, immune metabolism, and immunotherapy provide invaluable insights to aspiring scientists. Through lab courses on immune cell phenotyping and advanced techniques like spectral flow cytometry, he has empowered students with the skills to explore the complexities of immunology. His teaching contributions extend beyond knowledge dissemination, fostering a generation of critical thinkers and innovators.

📜 Accolades and Recognition

Bastian’s expertise has been recognized through his habilitation and venia legendi for Molecular Immunology, under the mentorship of Prof. Dr. Percy Knolle. His contributions as a scientific reviewer for prestigious journals like Hepatology, Journal of Hepatology, and Frontiers in Immunology further reflect his authority in the field. Additionally, his role in evaluating grant applications for the Deutsche Forschungsgemeinschaft (DFG) underscores his impact on shaping future research initiatives.

🌍 Impact and Influence

Through his research, teaching, and reviews, Bastian Höchst has left an indelible mark on the field of molecular immunology. His work not only uncovers critical mechanisms of immune regulation but also provides pathways for therapeutic advancements in inflammatory and tumor-related conditions. His contributions influence both scientific understanding and practical applications, addressing global challenges in health and disease management.

🌟 Legacy and Future Contributions

Bastian Höchst’s journey is one of passion, discovery, and impact. As he continues to lead groundbreaking research, he sets the stage for a future where immune-based therapies are revolutionized. His legacy lies in his ability to connect fundamental research with real-world applications, inspiring colleagues and mentees alike. With his unwavering commitment to scientific exploration, Bastian Höchst is poised to shape the future of molecular immunology, paving the way for transformative breakthroughs.

Publication

  • A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells
    Authors: B. Höchst, L.A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M.P. Manns, …
    Year: 2008

 

  • Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    Authors: B. Höchst, T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, …
    Year: 2009

 

  • Functional classification of memory CD8+ T cells by CX3CR1 expression
    Authors: J.P. Böttcher, M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Höchst, …
    Year: 2015

 

  • Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
    Authors: B. Höchst, J. Gamrekelashvili, M.P. Manns, T.F. Greten, F. Korangy
    Year: 2011

 

  • S100A9 a new marker for monocytic human myeloid‐derived suppressor cells
    Authors: F. Zhao, B. Höchst, A. Duffy, J. Gamrekelashvili, S. Fioravanti, M.P. Manns, …
    Year: 2012

 

  • Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
    Authors: T. Baumann, A. Dunkel, C. Schmid, S. Schmitt, M. Hiltensperger, K. Lohr, …
    Year: 2020

 

  • Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS
    Authors: D. Yuan, S. Huang, E. Berger, L. Liu, N. Gross, F. Heinzmann, M. Ringelhan, …
    Year: 2017

 

  • Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Authors: T.F. Greten, L.A. Ormandy, A. Fikuart, B. Höchst, S. Henschen, M. Hörning, …
    Year: 2010

 

Conclusion

Bastian Höchst’s career exemplifies dedication to advancing molecular immunology through innovative research, education, and mentorship. His contributions have shaped the understanding of immune responses in disease contexts, offering hope for novel therapeutic approaches. As he continues to lead impactful research and foster new talent, Bastian Höchst remains a visionary in his field, poised to drive future breakthroughs that bridge science and medicine for the benefit of society.

 

Hui-Hsin Ko | Oral oncology | Best Researcher Award

Posted on by Neuroscientists

Dr. Hui-Hsin Ko | Oral oncology | Best Researcher Award

Dr . Hui-Hsin Ko National Taiwan University Hsin-Chu Hospital Taiwan

Dr. Hui-Hsin Ko is an Assistant Professor and the Head of the Oral & Maxillofacial Surgery Division at National Taiwan University Hsin-Chu Hospital. With a DDS, MS, and PhD from National Taiwan University, she has extensive expertise in oral and maxillofacial surgery, specializing in cancer surgeries, temporomandibular joint (TMJ) surgeries, and zygomatic implantation. Dr. Ko’s research focuses on oral squamous cell carcinoma, with multiple publications in SCI-indexed journals. She has contributed significantly to the field of cancer research by exploring biomarkers such as AKR1B10, advancing both the understanding and treatment of oral cancers. Dr. Ko’s achievements in research and clinical practice have set a high standard for innovation in her field.

 

profile

scopus

Academic and Professional Background 🎓

Dr. Hui-Hsin Ko is a Clinical Assistant Professor at National Taiwan University and the Head of the Oral & Maxillofacial Surgery Division at National Taiwan University Hospital, Hsin-Chu Branch. She holds a DDS, MS, and PhD from National Taiwan University, with specialization in oral and maxillofacial surgery. Her expertise includes temporomandibular joint surgery, cancer surgery, and zygomatic implantation. A diplomate of the Taiwan Board of Oral and Maxillofacial Surgery, Dr. Ko has authored several publications, significantly contributing to oral squamous cell carcinoma research.

Research and Innovations 💡

Completed/Ongoing Research Projects: AKR1B10-related, TMJ arthroscopy-related, oral cancer-related.Citation Index: Information available on indexed platformsConsultancy/Industry Projects: To be updated Books Published (ISBN): No books published yet.Patents Published/Under Process: To be updated.Journals Published (SCI, Scopus, etc.): Multiple articles published in SCI-indexed journals

Editorial Appointments ✍️

To be updated.

Collaborations 🤝

Dr. Ko has actively collaborated with medical professionals and researchers in Taiwan to advance studies in oral squamous cell carcinoma and oral health-related surgeries.

Professional Memberships 📜

Diplomate of the Taiwan Board of Oral and Maxillofacial Surgery.Member of various oral and maxillofacial surgical associations

Areas of Research 🔬

Oral squamous cell carcinoma.Temporomandibular joint surgery.Zygomatic implantation.Cancer surgery

Contributions 🌟

Dr. Hui-Hsin Ko has significantly contributed to cancer research, especially in identifying biomarkers for oral squamous cell carcinoma progression. Her work on AKR1B10 levels has opened new pathways in understanding the poor prognosis of the disease. She has also explored advanced surgical techniques, including TMJ surgery and zygomatic implantation, contributing to improved patient outcomes.

 

📚 Publications

  • Title: The dental implant survival rate in 18 patients with post-operation revolutionary jaw reconstruction using free fibular flap, dental implants, and overdentures
    Author(s): Ko, H.-H., Chou, C.-H., Cheng, S.-J.
    Year: 2024

 

  • Title: Fibroblast growth factor 5 expression predicts the progression of oral squamous cell carcinoma
    Author(s): Shie, W.-Y., Cheng, S.-J., Chen, K.-C., Hou, H.-H., Elizabeth Chou, H.-Y.
    Year: 2024

 

  • Title: Oleanolic acid inhibits aldo-keto reductase family 1 member B10-induced cancer stemness and avoids cisplatin-based chemotherapy resistance via the Snail signaling pathway in oral squamous cell carcinoma cell lines
    Author(s): Ko, H.-H., Chou, H.-Y.E., Hou, H.-H., Yen-Ping Kuo, M., Cheng, S.-J.
    Year: 2024

 

  • Title: Prosthetic-Driven Autotransplantation with the Assistance of Medical Image-Processing Software and a Real-Time Navigation System: A Case Report
    Author(s): Chang, H.-M., Ko, H.-H., Chi, C.-W., Lin, I.-P., Chen, S.-H.
    Year: 2024

 

  • Title: Evaluation of the prognostic and therapeutic potential of inhibin beta B for oral squamous cell carcinoma
    Author(s): Chung, Y.-Y., Cheng, S.-J., Ko, H.-H., Shie, W.-Y., Elizabeth Chou, H.-Y.
    Year: 2024

 

  • Title: Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma
    Author(s): Ko, H.-H., Peng, H.-H., Cheng, A.N., Lee, A.Y.-L., Cheng, S.-J.
    Year: 2023

 

  • Title: Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3
    Author(s): Lu, Y.-J., Deng, Y.-T., Ko, H.-H., Kuo, M.Y.-P., Cheng, S.-J.
    Year: 2023

 

  • Title: ZNF582 hypermethylation as a prognostic biomarker for malignant transformation of oral lesions
    Author(s): Juan, Y.-C., Su, Y.-F., Bai, C.-H., Fwu, C.-W., Cheng, S.-J.
    Year: 2023

 

  • Title: β-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
    Author(s): Lo, Y.-W., Lee, A.Y.-L., Liu, Y.-C., Chiang, C.-P., Cheng, S.-J.
    Year: 2022

 

  • Title: Upregulated NPM1 is an independent biomarker to predict progression and prognosis of oral squamous cell carcinomas in Taiwan
    Author(s): Peng, H.-H., Ko, H.-H., Chi, N.-C., Kuo, M.Y.-P., Cheng, S.-J.
    Year: 2020

 

Conclusion

Dr. Hui-Hsin Ko’s extensive background in oral and maxillofacial surgery, coupled with her impressive research contributions to the understanding of oral squamous cell carcinoma, makes her a strong candidate for the Best Researcher Award. Her dedication to advancing cancer research, her innovative surgical techniques, and her collaborative efforts in the medical field demonstrate her leadership and impact. Dr. Ko has not only excelled in her clinical practice but has also significantly contributed to scientific advancements that benefit patients globally.